drugset / Trial / NCT00767598
The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects
RandomizedCrossoverOpen-labelBasic science
Summary
In order to evaluate the effect of CYP3A5\*3 allele on the pharmacokinetics of sildenafil, udenafil, and vardenafil, the clinical trial using a single oral dose was conducted in Korean healthy male subjects whose genotype of CYP3A5 had been determined.
Timeline
- Start
- 2007-12
- Primary completion
- 2007-12
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sildenafil | Unknown | 100 mg | Oral |
| Subject | Udenafil | Small molecule | 200 mg | Oral |
| Subject | Vardenafil | Small molecule | 20 mg | Oral |
Indications
No indication recorded.